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Objective: To assess the thyroid function in patients with acute pulmonary embolism, in
order to evaluate the prognostic value of thyroid hormones.
Methods: We studied 31 consecutive patients with acute pulmonary embolism.
Measured variables upon admission included the ratio of the partial pressure of oxygen in
arterial blood to the inspired oxygen fraction (PaO2/FiO2), acute physiology and chronic
health evaluation II score, risk stratiﬁcation indices and plasma levels of triiodothyronine,
free thyroxine, and thyroid stimulating hormone.
Results: Plasma levels of triiodothyronine were below normal level in 7 patients
(22.6%). Plasma triiodothyronine correlated with PaO2/FiO2 (P < 0.05) and with acute
physiology and chronic health evaluation II score (P < 0.01). In four patients (12.9%)
who died, triiodothyronine levels were signiﬁcantly lower (P < 0.01) than that in patients
who survived. In contrast both groups had similar levels of free thyroxine, and thyroid
stimulating hormone. Moreover, triiodothyronine levels negatively correlated with serum
markers of right ventricular dysfunction. Accordingly, in multivariate logistic regression
analysis, the only factors independently associated with an increased risk of death were
triiodothyronine and PaO2/FiO2.
Conclusions: Our preliminary data suggest that low plasma triiodothyronine is an in-
dependent predictor of in-hospital death in patients with acute pulmonary embolism.1. Introduction
A plethora of nonthyroidal illnesses are characterized by
thyroid function abnormalities, which are more prominent dur-
ing critical illness[1,2]. These abnormalities of the thyroid axis
have been collectively named as euthyroid sick syndrome[2,3]
or alternatively as nonthyroidal illness syndrome (NTIS)[4,5].
Mild cases of NTIS usually comprise decreased serum levels
of free (FT3) and total triiodothyronine (T3) and high levels
of reverse T3. However, as the severity and duration of the
underlying illness increase, both serum T3 and thyroxin (T4)
decrease, while thyroid-stimulating hormone (TSH) remains
normal or slightly decreased[1,2]. Previous studies have reported
low serum levels of thyroid hormones in multiple pathological
conditions including respiratory failure[6], sepsis[7,8], acute
respiratory distress syndrome[9], multiple trauma[10] and
surgery[11].Likewise, NTIS can be encountered in patients with cardio-
vascular diseases such as heart failure[12,13], acute myocardial
infraction[14–16] and cardiopulmonary bypass[17]. More
importantly, in the majority of these studies, thyroid
dysfunction has been associated with the severity and the
prognosis of the underlying disease. Nevertheless, the
interpretation of the hormonal components constituting NTIS
has been the cause of divergent opinions. Initially, the
aforementioned thyroid abnormalities were considered as
distinct from a clinically signiﬁcant state of hypothyroidism or
even as laboratory artifacts[18]. Meanwhile, other researchers
claim that the key element of NTIS is a combination of central
hypothyroidism with altered peripheral metabolism of T4 and
T3 that results in the reported depletion of thyroid hormones
from the circulation and tissues[19]. In this context, a thyroid
hormone replacement therapy has been proposed for the
reversal of NTIS[19], but the efﬁcacy of this therapeutic
modality has not been proven so far in terms of reduced
mortality.
Pulmonary embolism (PE) may result in high morbidity and
mortality, especially when associated with hemodynamic insta-
bility or signs of right ventricular (RV) dysfunction[20,21]. Current
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the prognostication of early mortality risk[20,21].
Hemodynamically unstable patients are included in the high-
risk group that is characterized by a short-term mortality
greater than 15%. Intermediate risk PE depends on the identi-
ﬁcation of either RV dysfunction or blood markers of myocar-
dial injury in patients with hemodynamic stability. Finally, the
low risk group includes the rest of the patients with acute PE.
Early mortality risk refers to in-hospital or 30-day mortality.
Nevertheless, prognostication in PE remains an unsettled issue
and there is an ongoing need for the identiﬁcation of markers
that can be incorporated into the clinical practice and improve
the predictive ability of early risk stratiﬁcation. Prognostic
assessment is also useful for the selection of the optimal treat-
ment for every risk class of patients. To date, no study has
determined the thyroid function in patients with acute PE.
Similarly, the prognostic ability of thyroid indices has not been
evaluated in this clinical setting. We therefore undertook a
prospective, observational study of a small cohort of patients
with acute PE. The aim of this study was to assess the thyroid
function and to test the ability of thyroid hormone levels to
predict in-hospital mortality in this group of patients.
2. Materials and methods
2.1. Study population
The present observational study was approved by the Insti-
tutional Ethics Committee. An informed, written consent was
obtained by every patient included in the study.
The study was conducted prospectively from August 2013
through August 2014 in a tertiary care hospital. We analyzed 39
consecutive patients admitted to the emergency room with PE,
conﬁrmed with computed tomographic pulmonary angiography.
A total of 4 patients were excluded due to previously diagnosed
intrinsic thyroid disorders, and 4 more patients were excluded
because of concomitant hormonal replacement therapy or
because they were receiving amiodarone or corticosteroids at
time of the admission. The ﬁnal study samples consisted of 31
patients.
Following the conﬁrmation of PE diagnosis, all patients
received supportive therapy at the time of admission and were
treated according to guidelines. Brieﬂy, oxygen was supplied to
achieve an arterial oxygen saturation of 92%. Hemodynami-
cally stable patients received standard anticoagulation therapy
with intravenous unfractionated heparin or subcutaneous low-
molecular-weight heparin. Thrombolytic therapy was conferred
for patients with hemodynamic instability and no high-risk of
bleeding. Collectively, 5 patients received thrombolysis (2-
h infusion of 100 mg recombinant tissue plasminogen activator).
2.2. Study protocol
At baseline, a structured clinical history and physical exam-
ination were carried out in all patients. Demographic and clinical
characteristics, including age, heart rate, respiratory rate, systolic
blood pressure and diastolic blood pressure of all patients were
obtained on admission to the Emergency Department. Arterial
blood gas sampling was performed, and the ratio of arterial
oxygen tension to inspired oxygen fraction (PaO2/FiO2) was
calculated. A 20-mL blood sample was taken and an intravenous
line was established shortly after admission to the EmergencyDepartment. In patients with compatible clinical history and/or
suggestive clinical ﬁndings, PE was conﬁrmed based on CT
pulmonary angiography. The co-existence of deep vein throm-
boembolism was assessed by lower extremity ultrasonography.
Patients with acute PE were classiﬁed, according to the risk of
PE-related early death, as high-, intermediate- and low-risk.
Initial risk stratiﬁcation was based on the presence of the
following risk markers.
Hemodynamic instability was diagnosed in patients that
fulﬁlled at least one of the following criteria[21]: 1) sustained
hypotension (systolic blood pressure < 90 mmHg or a
pressure decrease of 40 mmHg for more than 15 min at
arriving in the Emergency Department or requiring vasoactive
support) not attributable to an alternative diagnonis
(arrhythmia, acute left ventricular dysfunction, acute coronary
syndrome, hypovolemia, or sepsis); 2) pulselessness (cardiac
arrest); 3) persistent symptomatic bradycardia (heart rate <40
beats per minute with signs or symptoms of shock). Patients
with hemodynamic instability were considered affected by
high-risk PE and therefore as candidates for thrombolytic
therapy.
Elevated levels of cardiac troponin T (cTnT) (>100 pg/mL)
were considered as indicative of myocardial necrosis. RV
dysfunction was conﬁrmed by the presence of at least one of the
following: 1) RV systolic dysfunction on echocardiography
(echo); 2) RV dilation on CT or echo (apical 4-chamber RV
diameter divided by LV diameter >0.9); 3) elevation of N-ter-
minal pro-BNP (NT-Pro-BNP) (>500 pg/mL); or 4) electro-
cardiographic changes (new complete or incomplete right bundle
branch block, anteroseptal ST elevation or depression, or ante-
roseptal T-wave inversion). Hemodynamically stable patients
with conﬁrmed acute PE and ﬁndings compatible with RV
dysfunction and/or myocardial necrosis were classiﬁed as
intermediate-risk patients.
Finally, hemodynamically stable patients with acute PE and
no RV dysfunction or myocardial necrosis were considered as
low risk patients.
All patients with diagnosed acute PE were followed up
during their hospitalization. The end point of the study was
death in the pulmonary clinic due to PE.
2.3. Measurements
At baseline, acute physiology and chronic health evaluation
II (APACHE II) score (range from 0 to 71) was calculated based
on the appropriate initial clinical, demographic and serological
characteristics of each patient. Echocardiography was performed
by a skilled cardiologist using standard views with a GE VIVIDi
ultrasound device (General Electric Company, Wauwatosa, WI,
USA) using 2.4 MHz multiplane transducer.
Thyroid function was assessed at admission by measurement
of plasma levels of T3, free T4 (fT4), and TSH. Thyroid function
was reevaluated upon discharge from the respiratory clinic by
measurement of the same parameters. T3, fT4 and TSH were
measured by immunochemiluminometric assay on the Roche
Modular E170 Analytics (Roche Diagnostics GmbH, Man-
nheim, Germany). The normal ranges of serum hormone con-
centrations in our laboratory are as follows: 80–200 ng/dL for
T3, 0.93–1.7 ng/dL for fT4 and 0.27–4.2 mIU/mL for TSH.
Serum creatinine and albumin levels were determined on a
Roche/Hitachi Modular System P (Roche Diagnostics GmbH,
Mannheim, Germany) by enzymatic assay. Serum cTnT levels
Table 1
Characteristics of study population at admission.
Characteristics Median (range)
or number (%)
Age (years) 65.7 (20–95)
Sex (male) 13 (42)
APACHE II score 16 (4–27)
Blood gases
PaO2/FiO2 328 (130–450)
PaO2 (mmHg) 88.7 (41–137)
PaCO2 (mmHg) 36.4 (22.3–62.9)
HCO3 (mmol/L) 23.1 (13.4–28.2)
Thyroid hormones
T3 (ng/dL) 93.61 (54.5–152.4)
fT4 (ng/dL) 1.33 (0.70–1.80)
TSH (mIU/mL) 2.13 (0.2–4.5)
Creatinine (mg/dL) 1.11 (0.42–2.76)
Albumin (mg/dL) 3.6 (2.5–4.6)
d-dimers (mg/L) 3.3 (0.37–10.39)
cTnT (pg/mL) 47 (3–225.8)
NT-pro-BNP (pg/mL) 842.81 (10.38–4229)
Echo or ECG indices of RV dysfunction 9 (29)
DVT 16 (51.6)
PaCO2: partial pressure of carbon monoxide, arterial; DVT: deep venous
thromboembolism; ECG: electrocardiogram.
Figure 1. Relationship between plasma levels.
A: Relationship between plasma levels of T3 and the ratio of the partial
pressure of oxygen in arterial blood to the fraction of oxygen in inspired gas
(PaO2/FiO2); B: Relationship between plasma levels of T3 and APACHE II
score. Data were obtained in 31 patients with acute pulmonary embolism
upon admission to the pulmonary department.
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assay on a Roche modular system E170 (Roche Diagnostics
GmbH, Mannheim, Germany). Serum NT-pro-BNP was deter-
mined using an electrochemiluminescence immunoassay method
(NT-pro-BNP, Roche) with a Roche modular E170 immuno-
assay analyzer (Roche Diagnostics GmbH, Mannheim,
Germany).
For the measurement of the aforementioned parameters in all
eligible subjects blood samples were obtained shortly after the
admission of patients to the Emergency Department. Therefore,
in all the cases, blood was obtained before the administration of
anticoagulants or thrombolysis.
2.4. Statistical analysis
The comparison of means of continuous variables was per-
formed by the unpaired-samples Mann–Whitney test and the
paired-samples Wilcoxon test. Results are reported as medians
and ranges, while categorical variables are expressed as per-
centages. The possibility of a linear association between vari-
ables was assessed by Spearman's correlation coefﬁcient (r).
Univariate logistic regression analyses were performed to
examine the association between mortality and each of the
predictors separately in order to identify factors signiﬁcantly
associated with an increased risk of death; for each variable, the
odds ratio (OR), and 95% conﬁdence interval (CI), are given. All
variables with P < 0.1 were then tested in a multivariable lo-
gistic regression analysis model aiming to identify the inde-
pendent predictors of in-hospital mortality.
A two-sided P value less than 0.05 was considered statisti-
cally signiﬁcant. All analyses were performed using SPSS
version 13.0 software (SPSS, Inc, Chicago, IL, USA).
3. Results
In 7 out of 31 patients (22.6%) plasma levels of T3 were
below normal range, while fT4 plasma concentrations were
below normal level in 1 patient only (3.2%). TSH plasma levels
were below the normal range in 1 patient (3.2%). Patients'
baseline clinical and laboratory data are reported in Table 1.
No signiﬁcant difference was detected between fT4 or TSH
levels at admission (median fT4 1.4 ng/dL; median TSH
1.9 mIU/mL) compared with the respective levels at the time of
discharge (median fT4 1.34 ng/dL, median TSH 2.1 mIU/mL).
On the contrary, T3 levels upon discharge were normalized
being higher (P < 0.05, median T3 97.3 ng/dL; range: 73–
143 ng/dL) than T3 levels at admission (median T3 86.7 ng/dL;
range: 54.5–152.4 ng/dL). Initial plasma concentrations of T3
were signiﬁcantly correlated (r = 0.435, P < 0.05) with the
severity of gas exchange impairment in terms of PaO2/FiO2 ratio
(Figure 1A). Moreover, a signiﬁcant inverse correlation
(r = −0.502, P < 0.01) was found between T3 levels and
APACHE II score (Figure 1B).
Four (12.9%) of the 31 patients died during their stay in the
pulmonary clinic. Three of these patients were initially classiﬁed
as high-risk patients, while 1 patient belonged in the group of
intermediate risk. No signiﬁcant difference was observed be-
tween these patients and those who survived as to age, sex, fT4,
TSH and albumin or creatinine. On the other hand, patients who
died were characterized by signiﬁcantly lower T3 levels (un-
paired t-test; P < 0.01; median T3 60.3 ng/dL; range, 54.5–
80.0 ng/dL, n = 4), in comparison with patients who survived(median T3 92.8 ng/dL; range, 67.1–152.4 ng/dL, n = 27) as
shown in Figure 2.
APACHE II score was also signiﬁcantly lower in patients
who died (median APACHE II score, 28.25; range, 26–32,
n = 4) than that in those who survived (median APACHE II
score, 13.07; range, 2–29 pg/ml, n = 27). Pulmonary gas ex-
change impairment was signiﬁcantly greater (P < 0.01, unpaired
t-test) in patients who died (median PaO2/FiO2 ratio 175; range
127–212, n = 4) than in those who survived (median PaO2/FiO2
ratio 319.59; range 130–450, n = 27). Finally, cTnT levels were
signiﬁcantly higher (P < 0.05, unpaired t-test) in patients who
died (median cTnT 103.38 pg/mL; range 53–193 pg/mL, n = 4)
than in those who survived (median cTnT 38.72 pg/mL; range
3–225.8 pg/mL, n = 27).
Figure 2. Difference of plasma T3 levels between survivors (n = 27) and
non-survivors (n = 4) from acute PE.
T3 levels were compared by analysis of variances. **: P < 0.01 vs. non-
survivors.
Table 3
Univariate logistic regression analysis for variables associated with
mortality in patients with acute PE.
Variables P OR 95% CI
T3 0.028 1.229 1.022–1.477
PaO2/FiO2 ratio 0.083 1.013 0.998–1.028
APACHE II score 0.110 0.592 0.84–1.040
cTnT 0.075 0.987 0.973–1.001
Age 0.309 0.965 0.901–1.034
FT4 0.946 1.172 0.012–113.577
TSH 0.696 0.850 0.376–1.921
Albumin 0.141 4.691 0.598–36.806
NT-pro-BNP 0.891 1.000 0.999–1.001
Table 4
Multivariate logistic regression analysis of risk factors associated with
mortality in patients with acute PE.
Variables P OR 95% CI
T3 0.034 1.226 1.016–1.479
PaO2/FiO2 ratio 0.047 1.007 0.987–1.028
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patients with hemodynamic instability (P < 0.05; median T3
72.48 ng/dL; range 54.5–102.7 ng/dL, n = 5) or in patients with
RV dysfunction or myocardial necrosis (P < 0.01; median T3
80.61 ng/dL; range 62.5–95.8 ng/dL, n = 8) compared with low
risk patients (median T3 102.15 ng/dL; range 75.90–152.4 ng/
dL, n = 18). In contrast, no signiﬁcant difference in TSH and fT4
levels was detected between the three groups of patients. In
accordance with these ﬁndings, a signiﬁcant inverse correlation
was found between T3 and cTnT (Spearman's r = −0.462,
P < 0.01) or NT-pro-BNP levels (r = −0.464, P < 0.01). No
signiﬁcant correlation was observed between serum fT4 or TSH
and cTnT or NT-pro-BNP levels. The correlation analysis of
thyroid hormones levels and serum markers of myocardial injury
and RV function is showed in Table 2.
APACHE II score was also signiﬁcantly lower in high-risk
patients (P < 0.01; mean APACHE II score 26.2 ± 2.51,
n = 5) and intermediate risk patients (P < 0.05; mean APACHE
II score, 19 ± 1.94, n = 8) compared with low risk patients (mean
APACHE II score, 10.16 ± 1.58, n = 18). Furthermore, PaO2/
FiO2 ratio was signiﬁcantly lower in patients with hemodynamic
instability (P < 0.05; mean PaO2/FiO2 208.2 ± 33.72, n = 5)
compared with low risk patients (mean PaO2/FiO2
323.67 ± 21.58, n = 18). In this study sample, none of the
thyroid parameters was correlated with length of in hospital stay.
The length of in hospital stay was negatively correlated with
PaO2/FiO2 ratio (r = −0.395, P < 0.05) and positively correlated
with APACHE II score (r = 0.518, P < 0.01) and troponin levels
(r = 0.577, P < 0.001).
In univariate logistic regression analysis, the only factor
signiﬁcantly associated with an increased risk of death was T3
(OR = 1.229; 95% CI 1.022–1.477, P = 0.028) (Table 3).Table 2
Correlation analysis of thyroid hormones levels with serum markers of
myocardial injury and cardiac function.
Variables cTnT NT-pro-BNP
T3 r = −0.574, P < 0.01 r = −0.460, P < 0.01
fT4 r = −0.21, P = 0.909 r = 0.075, P = 0.69
TSH r = −0.45, P = 0.811 r = 0.051, P = 0.786Multivariate logistic regression analysis, including variables
with P < 0.1, was performed to identify factors with independent
predictive value for in hospital mortality, controlling for possible
confounders. T3 was independently related to increased risk of
death (OR = 1.229; 95% CI 1.022–1.477, P = 0.028). The results
of multivariate analysis are shown in Table 4.
4. Discussion
This preliminary prospective study evaluated and tested the
prognostic value of thyroid hormones measured at admission in
a small cohort of patients with acute PE. A literature search
revealed that the present study is the ﬁrst to investigate the
thyroid status in patients with acute PE. Of the 31 patients
included in the analysis, reduced T3 levels were found in 22.6%
of the patients, while fT4 and TSH plasma levels were reduced
in only 1 patient. Plasma levels of T3 were related to severity,
risk status and gas exchange defect, as reﬂected by APACHE II
score, the levels of cTnT and NT-pro-BNP and PaO2/FiO2 ratio
respectively. The remaining two of the evaluated indicators of
thyroid function, TSH and fT4, did not show any association
with the aforementioned parameters. In several previous studies,
low plasma T3 or fT3 levels are associated with severity scores
such as APACHE II score and/or a worse prognosis of the un-
derlying disease in critical ill patients[6,8,10,12,18,22]. Furthermore,
lower fT3 levels have been reported in patients with
respiratory failure from different pulmonary disorders[6]. In the
past, NTIS had long been considered as an adaptive
physiologic response, but growing evidence suggests that this
syndrome may contribute or directly promote clinical
deterioration in the setting of a critical illness[5,19].
In our study, plasma T3 levels were signiﬁcantly lower in
non-survivors than those who survived to hospital discharge.
Conversely, there was no difference in age, sex and metabolic
parameters between the two groups of patients. In fact, T3 was
the only thyroid indicator that proved to be an independent
predictor of in-hospital mortality in logistic regression analysis.
Similarly, a number of previous studies have demonstrated low
plasma T3 levels as a predictor of worse clinical outcome in
Sotiris Kakavas et al./Journal of Acute Disease 2015; 4(3): 196–201200various cardiovascular disorders[23,24] including heart failure[13,25],
coronary artery disease[26] or patients with coronary artery
bypass[17]. In addition, our results show that T3 levels were
signiﬁcantly lower in patients with risk factors of early
mortality compared with low-risk patients. More interestingly,
plasma T3 negatively correlated with cTnT or NT-pro-BNP
levels which have been shown to be independent predictors of
short-term mortality in patients with acute PE[20,21]. Therefore, we
could hypothesize that the T3 level may serve as an indicator of
hemodynamic compromise, poor RV function or myocardial
injury in patients with PE.
There is still great uncertainty concerning the possible in-
teractions between lower plasma fT3 or T3 levels and the major
pathophysiological pathways implicated in critical cardiopul-
monary distress. Low T3 serum concentrations have been
associated with cardiac function and NT-pro-BNP levels in pa-
tients with heart failure[13,25,26] or acute coronary syndromes[12].
Recently, fT3 levels have been also correlated with
echocardiographic and serum markers of myocardial
dysfunction and injury including serum cardiac troponin I in
patients with acute myocardial infraction[16,27]. Moreover, the
elevation of serum T3 levels above normal by the intravenous
administration of T3 in patients with coronary artery bypass
was coupled with enhanced cardiac output and reduced need
for vasoactive support[28]. Relevantly, endogenous T3 has been
shown to possess positive inotropic and chronotropic
properties[29]. Furthermore, it appears to promote a more
efﬁcient diastolic relaxation, thus improving the myocardial
metabolism[30]. Finally, T3 exhibits a rapid upregulating effect
on the rat alveolar epithelial Na-K-ATPase that enhances the
removal of edema ﬂuid from the alveolar space[31]. On the other
hand, small clinical studies of thyroid hormone replacement
therapy in critically ill patients with NTIS failed to
demonstrate an improvement in survival[32,33].
In summary, our preliminary clinical study suggests that
plasma T3 levels may be used as a predictor of outcome in
patients with PE. Furthermore, T3 levels correlated with other
markers indicating the risk of PE-related early death. In other
words, T3 levels may be as an additional marker for the strati-
ﬁcation of patients with PE depending on the risk of in-hospital
or short-term death. The small size of our study sample hinders
any attempt to further clarify if this low T3 state represents an
adaptive response to stress that coincides with respiratory and/or
circulatory compromise or if it actually contributes to the path-
ogenesis of this compromise. In any case, the potential prog-
nostic ability of thyroid indicators such as T3 seems compatible
with the role of thyroid hormones in maintaining homeostasis
and promoting adaptation in the face of acute stress through
modulation of various multifactorial mechanisms. The pre-
liminary observations of our study require further validation in
larger populations in order to clarify the underlying mechanisms
implicating thyroid dysfunction during acute PE. Larger studies
may also warrant the investigation of a possible beneﬁt from
reversal of NTIS by thyroid hormone replacement therapy in
patients with acute PE. This therapeutic modality could be
conferred for the subgroup of patients with increased risk of
early death caused by acute PE.
The present study has its limitations. To begin with, for the
assessment of thyroid function we used a selected panel of
thyroid indicators (T3, fT4, TSH) which is commonly used by
our laboratory in every day practice. Generally, plasma T3 and
fT3 are both reduced in NTIS. However, T3 or T4 levels arepartly dependent upon the concentration or the binding ability of
binding proteins mainly thyroxine-binding globulin. Therefore
T4 and to a lesser degree T3 levels may be affected by various
pathological conditions (for example liver insufﬁciency) or by a
number of therapeutic agents. On the other hand, the measure-
ment of T3 in hospitalized patients is useful for the recognition
of nonthyroidal illness due to the decreased 50-monodeiodinase
activity. It is possible that a more extensive testing for thyroid
function (T3, fT3, reverse T3, T4, fT4, TSH) would provide a
more integrative evaluation, but this was not within the available
resources of our institution.
Second, although patients with overt thyroid disorders were
excluded, the probability of previously undiagnosed thyroid
disease in some patients before admission could not be
completely ruled out in the present study. In addition, given that
numerous drugs may affect the thyroid axis, it is difﬁcult to adjust
for every one of these drugs. However, patients receiving amio-
darone, corticosteroids or any kind of replacement therapy were
excluded from the study, while blood samples were obtained from
patients at the time theywere admitted to the emergency room and
before the administration of any anticoagulant agent.
In conclusion, in this preliminary study, baseline plasma T3
was a predictor of mortality in patients with acute PE. T3 levels
signiﬁcantly correlated with the severity as reﬂected by the
APACHE II score and with impairment of oxygenation as re-
ﬂected by the PaO2/FiO2 ratio. Furthermore, T3 levels correlated
with baseline NT-pro-BNP and cTnT levels that are used for the
early stratiﬁcation of patients as markers indicating the risk of
early death from PE.
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